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& dhfrXII) and chloramphenicol (catB3) and correlated to
their antimicrobial susceptibility phenotypes. A new combi-
nation of gene cassettes (dfrA15- aadA1) was found in one
of the strains studied. The complete sequences of these
gene cassettes have been submitted to the GenBank and
Accession Numbers have been assigned.
doi:10.1016/j.ijid.2008.05.1055
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Background: Continuous vancomycin infusion is increas-
ingly used for outpatient management of infections, but the
relationship between vancomycin and nephrotoxicity is con-
troversial. We investigated the risk factors associated with
nephrotoxicity in this setting.
Methods: A retrospective cohort study of patients receiv-
ing continuous vancomycin infusion as Outpatient Parenteral
Antibiotic Therapy (OPAT) was performed. The likelihood
of developing nephrotoxicity (≥50% increase in serum
creatinine from baseline) was evaluated in relation to
demographic variables, underlying co-morbidities, infec-
tious disease diagnoses, concomitant drug exposures and
vancomycin concentration. Logistic regression was used to
determine the association of various variables. Classiﬁcation
and regression tree analysis was used to determine the most
signiﬁcant breakpoint for continuous variables.
Results: We examined 102 adult patients between Jan-
uary 2004 and June 2007. The mean± SD age, baseline
serum creatinine and steady state vancomycin concen-
tration were 48.2± 17.6 years, 78.0± 32.5mol/L and
15.5± 10.8mg/L, respectively. The majority of the patients
(66.7%) were treated for bone and joint infection.
The cumulative incidence of nephrotoxicity was 15.7%.
Nephrotoxicity was found to be associated with hyper-
tension [odds ratio (OR) 5.302 (95% conﬁdence interval
{CI}1.159—24.246), p = 0.031], exposure to aminoglycosides
[OR 6.594 (95% CI 1.026—42.385), p = 0.047], loop diuret-
ics [OR 8.123 (95% CI 1.449—45.528), p = 0.017], and steady
state vancomycin concentration≥ 28mg/L [OR 21.236 (95%
CI 2.687—167.857), p = 0.004].
Conclusion: We have identiﬁed independent risk factors
for nephrotoxicity in patients receiving continuous infusion
vancomycin in OPAT. A serum steady state vancomycin con-
centration≥ 28mg/L markedly increases this risk.
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Background: To compare the efﬁcacy and safety of
piperacillin/tazobactam with cefepime as an empiri-
cal monotherapy for adult cancer patients with febrile
neutropenia. Method: A prospective, randomized, open-
labelled, comparative trial was performed. If clinically
preferable, the test article may be changed to oral
ciproﬂoxacin at 72 hours. Clinical and microbiological
responses were determined at 72 hours and at the end of
therapy.
Results: A total of 89 cases were enrolled. 48 patients
received piperacillin/tazobactam (PT group) and 41 patients
received cefepime (CA group). Demographic and clinical
characteristics were similar in two groups (p > 0.05). Clin-
ical success rate at 72 hours in PT group (91.7%) was similar
to that in CA group (85.4%) (p = 0.31). At the end of therapy,
clinical success rate in PT group (91.7%) was also similar to
that in CA group (100%) (p = 0.15). Adverse events including
liver dysfunction (21.3%) and renal dysfunction (2.2%) were
similar in two groups (p = 0.87).
Conclusion: piperacillin/tazobactammonotherapy was as
effective and safe as the cefepime as an empirical treatment
for cancer patients with febrile neutropenia.
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Cationic antimicrobial peptides (AMPs) are important
mediators in the primary host defense system against
pathogenic microorganisms and are widely distributed
in nature. The occurrence and characterization of low-
molecular-mass AMPs from a wide variety of organisms have
been accumulating at a rapid rate because of their biochem-
ical diversity and broad speciﬁcity against bacteria or fungi
and even some being anti-viral or possessing wound-healing
effects. This has biopharmaceutical applications especially
in view of the increased bacterial resistance to antibiotics in
the clinical setting over the past decade. There is a growing
need to discover and introduce new drugs, and AMPs provide
new promising candidates as new antibiotics. The objective
of this study has been to isolate novel peptides from native
microbial and plant sources including fermented extracts.
The antimicrobial properties of these extracts were ini-
tially tested using Escherichia coli, Staphylococcus aureus
and Bacillus subtilis. This paper shows the initial results of
the inhibition obtained on these microorganisms using plant
and fermented extracts. The extracts were fractionated
using cation exchange chromatography and antimicrobial
tests were conducted with the fractions obtained. High pres-
sure liquid chromatography was attempted with one of the
extracts and some preliminary results were also obtained.
